Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

Eli Lilly is paying up to $630m for a Phase I metabolic-associated steatohepatitis ... development for the treatment of ...

In honor of American Heart Month, Healio Dermatology interviewed experts and explored the connection between skin disease and heart health.The discovery of this relationship can be traced back to ...

UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...

Equities research analysts at StockNews.com began coverage on shares of vTv Therapeutics (NASDAQ:VTVT – Get Free Report) in a research report issued on Saturday. The brokerage set a “sell” rating on ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.